Press Releases Choose Year All Items 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Search Press Releases Found 211 Results May 3, 2018 Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates April 26, 2018 Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018 April 9, 2018 Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder March 15, 2018 Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22 March 12, 2018 Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates March 5, 2018 Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018 February 5, 2018 Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director December 21, 2017 Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder December 19, 2017 Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia December 11, 2017 Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors «...1011121314...20...»